Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07226570 · ClinicalTrials.gov registry record
Mapping Ibogaine Neural Dynamics in Opioid Use Disorder
A clinical trial of Opioid Use Disorder (OUD), sponsored by University of California, Irvine.
- Recruiting
- Registry status
- 20
- Enrollment target
- 1
- Study location
NCT07226570: Recruiting study of Opioid Use Disorder (OUD), sponsored by University of California, Irvine.
NCT07226570 is a study of Opioid Use Disorder (OUD) that is actively recruiting participants, run by University of California, Irvine. The registered enrollment target is 20 participants, below the 315-participant average among 7 other Opioid Use Disorder (OUD) trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07226570, a study of Opioid Use Disorder (OUD), is actively recruiting participants, sponsored by University of California, Irvine.
- RECRUITING
- Registry status
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This study aims to understand how ibogaine treatment may change brain activity and symptoms in people with moderate-severe opioid use disorder (OUD), as defined by the DSM-5. Ibogaine is a plant-derived compound that some studies suggest can reduce opioid cravings and withdrawal. Participants in this study will already be independently scheduled to receive legal ibogaine treatment at a licensed clinic outside of the U.S. The University of California, Irvine (UCI) research team will not provide the treatment but will conduct brain imaging, administer psychometric questionnaires, and obtain urine samples throughout the course of this study. The main goal is to see if ibogaine changes brain function as assessed with magnetic resonance imaging (MRI), magnetic resonance spectroscopy (MRS), and electroencephalography (EEG). MRI/MRS will measure brain activity when participants view opioid-related images, brain connectivity at rest, and levels of brain chemicals involved in craving and substance use. EEG will measure brain wave activity. MRI/MRS/EEG will be administered across 3 study time points. In addition, participants will complete psychometric surveys related to opioid craving, withdrawal symptoms, mood, anxiety, pain, and quality of life, along with urine tests to monitor substance use and screen for pregnancy. The investigators hypothesize that after ibogaine treatment, participants will show reduced brain responses to opioid cues, changes in brain connectivity and chemistry, and improvements in self-reported cravings and other symptoms. This information may help researchers better understand how ibogaine works in the brain and whether it could play a role in future treatments for OUD.
Primary Outcome
Resting-state functional MRI will assess functional connectivity within reward circuitry, including the basal ganglia, nucleus accumbens, cingulate cortex, hippocampus, insula, and amygdala. Connectivity will be quantified using correlation coefficients between regional BOLD signals. Unit of Measure: Correlation coefficient (range: -1 to +1, where higher values indicate stronger positive connectivity)
Conditions Studied
Interventions
- OTHER Observational study with MRI/EEG
Study Locations (1)
California
- Susan Samueli Integrative Health Institute, University of California, Irvine - Irvine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2025-09-08 |
| Est. Completion | 2027-05 |
What NCT07226570 shows while recruiting
NCT07226570 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 315-participant average among 7 other Opioid Use Disorder (OUD) trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Opioid Use Disorder (OUD) appearing as the primary indexed condition, and to 1 intervention - of which Observational study with MRI/EEG is the first listed.
NCT07226570 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT07226570 about?
NCT07226570 is a clinical study titled "Mapping Ibogaine Neural Dynamics in Opioid Use Disorder". This study aims to understand how ibogaine treatment may change brain activity and symptoms in people with moderate-severe opioid use disorder (OUD), as defined by the DSM-5. Ibogaine is a plant-derived compound that some studies suggest can reduce opioid cravings and withdrawal. Participants in thi...
What is the current status of trial NCT07226570?
This trial is currently recruiting. The enrollment target is 20 participants. The study started on 2025-09-08. Estimated completion is 2027-05.
What conditions does trial NCT07226570 study?
This clinical trial studies the following conditions: Opioid Use Disorder (OUD).
What interventions are being tested in trial NCT07226570?
The interventions under investigation include: Observational study with MRI/EEG (OTHER).
Who is sponsoring clinical trial NCT07226570?
This trial is sponsored by University of California, Irvine, which has 368 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07226570 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Opioid Use Disorder (OUD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Adjunctive Cannabidiol for Recovery From Opioid Study
RECRUITING · Phase 3
-
Opioid Adherence and Support Through Innovative Texting Strategies
RECRUITING · NA
-
Individualized Adaptive Deep Brain Stimulation in Opioid Use Disorder
RECRUITING · NA
-
MethaLoad Dose-Finding Study
RECRUITING · Phase 1
-
HEALing Communities Study
ACTIVE NOT RECRUITING · NA
-
Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD)
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI